Endocrine Abstracts

Background: Adrenocortical cancer (ACC) therapy is characterized by insufficient effectiveness. Currently, mitotane, an adrenolytic drug, is the only drug approved for treatment of ACC and is used in the adjuvant setting and in case of metastatic or advanced disease. However, the administration of mitotane to certain groups of patients remains controversial due to the low response rates, high toxicity and limited data on the benefit of treatment. Expression levels of the large...

Background: Adrenocortical carcinoma (ACC) is a rare malignant tumor with a poor prognosis. The only curative therapy is complete surgery (R0). A 5-year local recurrence and distant metastasis rate after R0 is 80–85%. Mitotane is widely used as an adjuvant treatment in patients with a high risk of recurrence. According to the most studies, it can delay and possibly prevent a recurrence of the disease in 35–50%. However, its efficacy is controversial, as well as the o...

Introduction: Adrenocortical carcinoma (ACC) is a rare malignant tumor with heterogeneous prognosis. The median overall survival of all ACC patients is about 3-4 years. Complete surgical resection provides the only cure [Fassnacht M, et al., 2018]. In cases of advanced ACC, therapeutic options are limited. No effective second-line therapies are recommended for patients with disease progression to EDP chemotherapy scheme and Mitotane. It is essential to study alternative drugs,...